Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics. Leveraging expertise in RNA-modifying proteins (RMPs) and the systemic mapping of both the RMP space and adjacent high-value areas for drug discovery, Accent employs a flexible model that allows for a diversity of approaches to developing potentially transformative biomarker-driven cancer medicines. Accent is advancing innovative treatments designed for both novel and known, but suboptimally-addressed, high-impact oncology targets offering the potential to benefit large patient populations with significant unmet need. The company’s clinical-stage assets include ATX-559, a first-in-class DHX9 inhibitor, and ATX-295, a potentially best-in-class KIF18A inhibitor, both of which are currently being evaluated in Phase 1/2 clinical trials.
MassBio Member Spotlight: Accent Therapeutics, Inc.
Location: Lexington, MA
Website: accenttx.com
Leadership:
- Shakti Narayan, PhD, JD | Chief Executive Officer
- Serena Silver, PhD | Chief Scientific Officer
- Jason Sager, MD | Chief Medical Officer
- David Brower, MBA | Chief Business Officer and Head of Finance
Therapeutic Area: Oncology
